Literature DB >> 14605132

Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population.

Sook-Yin Lui1, Khay-Guan Yeoh, Bow Ho.   

Abstract

The trend of increasing prevalence of antibiotic resistance among Helicobacter pylori strains has been suggested as a cause of the failure of treatment of H. pylori infections. In this study, 120 of 211 antral biopsy specimens from patients with dyspeptic symptoms were found to harbor H. pylori. The isolates from the 120 specimens were tested by the agar dilution method, and 38 (31.7%) were found to be metronidazole resistant. Among the 211 subjects, 81 of 115 (70.4%) patients with peptic ulcer (PU) were infected with H. pylori, whereas 39 of 96 (40.6%) patients with nonulcer dyspepsia (NUD) were infected with H. pylori. Interestingly, significantly more NUD patients than PU patients harbored metronidazole-resistant H. pylori (22 of 39 [56.4%] and 16 of 81 [19.8%], respectively; P < 0.001). A similar pattern was also observed among NUD patients of different ethnicities but not between male and female patients (23 of 78 [29.5%] and 15 of 42 [35.7%], respectively; P = 0.54). In the posttreatment follow-up, five of six patients who had positive urea breath test results, indicating treatment failure, were NUD patients. Of these, four harbored metronidazole-resistant H. pylori strains. This further illustrates the relevance of metronidazole-resistant H. pylori in NUD patients. The significantly higher percentage of metronidazole-resistant H. pylori isolates in NUD patients may be attributed to the protection offered by the mucus layer of the nonulcerated stomach to the bacteria that reside below it, resulting in organism exposure to sublethal concentrations of metronidazole and leading to the induction of metronidazole resistance. The results demonstrate that the H. pylori isolates colonizing NUD patients are more likely to be resistant to metronidazole. It will therefore be useful to reevaluate the use of metronidazole in the treatment of NUD patients infected with H. pylori.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605132      PMCID: PMC262534          DOI: 10.1128/JCM.41.11.5011-5014.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Recommendations for susceptibility tests on fastidious organisms and those requiring special handling.

Authors:  A King
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

2.  Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.

Authors:  F Mégraud; N Lehn; T Lind; E Bayerdörffer; C O'Morain; R Spiller; P Unge; S V van Zanten; M Wrangstadh; C F Burman
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy.

Authors:  F Mégraud
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-08       Impact factor: 2.566

Review 4.  Diagnosis of Campylobacter pylori infections: the "gold standard" and the alternatives.

Authors:  J S Barthel; E D Everett
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

5.  Improving the success of culturing Helicobacter pylori from gastric biopsies.

Authors:  J Hua; K G Yeoh; H C Ng; P Y Zheng; S G Lim; B Ho
Journal:  Microbios       Date:  1998

6.  Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands.

Authors:  Y J Debets-Ossenkopp; A J Herscheid; R G Pot; E J Kuipers; J G Kusters; C M Vandenbroucke-Grauls
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

7.  The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori.

Authors:  A Pilotto; G Leandro; M Franceschi; M Rassu; L Bozzola; F Furlan; F Di Mario; G Valerio
Journal:  Aliment Pharmacol Ther       Date:  1999-05       Impact factor: 8.171

8.  Prevalence of metronidazole-resistant Helicobacter pylori in dyspeptic patients.

Authors:  H X Xia; M A Daw; S Beattie; C T Keane; C A O'Morain
Journal:  Ir J Med Sci       Date:  1993-03       Impact factor: 1.568

9.  Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori.

Authors:  Y Glupczynski; M Labbé; W Hansen; F Crokaert; E Yourassowsky
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

10.  Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice.

Authors:  P J Jenks; A Labigne; R L Ferrero
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

View more
  4 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Antibiotic resistance pattern and frequency of cagA and vacA genes in Helicobacter pylori strains isolated from patients in Tabriz city, Iran.

Authors:  Farnaz Rasi-Bonab; Abolfazl Jafari-Sales; Mohammad Amin Shaverdi; Tahereh Navidifar; Morteza Saki; Atosa Ghorbani; Abimbola Olumide Adekanmbi; Behboud Jafari; Sara Naebi
Journal:  BMC Res Notes       Date:  2021-05-31

3.  Laboratory diagnosis and susceptibility profile of Helicobacter pylori infection in the Philippines.

Authors:  Raul V Destura; Eternity D Labio; Leah J Barrett; Cirle S Alcantara; Venancio I Gloria; Ma Lourdes O Daez; Richard L Guerrant
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-11-16       Impact factor: 3.944

4.  Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur.

Authors:  Xinsheng Teh; Yalda Khosravi; Woon Ching Lee; Alex Hwong Ruey Leow; Mun Fai Loke; Jamuna Vadivelu; Khean Lee Goh
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.